此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Insulin Sensitivity in Men With the Metabolic Syndrome

Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome

The metabolic syndrome is a medical condition defined by high levels of cholesterol in the blood, high blood pressure, central obesity (gain in fat around the region of the stomach), and insulin resistance (body responds less well to insulin). This state of impaired insulin resistance can lead to type 2 diabetes mellitus, which is one of the most common metabolic disorders in the U.S. Numerous studies have shown an inverse relationship between insulin resistance and testosterone levels in men, however, causality has not been established. This protocol investigates the role of testosterone in modulating insulin sensitivity in insulin resistant states such as the metabolic syndrome. The hypothesis is that testosterone administration will improve insulin sensitivity.

研究概览

详细说明

This protocol will address the impact of three months of testosterone (T) therapy on all components of the metabolic syndrome and the mechanism underlying changes in insulin sensitivity by analyzing changes in body composition, and detailed studies of fat metabolism and skeletal muscle. In addition, this protocol will address the role of estradiol (E2) in mediating the effect of testosterone on insulin sensitivity.

Seventy-two subjects will be enrolled. Study subjects will undergo a screening visit to assess eligibility after which a baseline metabolic assessment will be performed including a a fasting oral glucose tolerance test (OGTT) to measure normal glucose and insulin metabolism, an intravenous glucose tolerance test (IVGTT) to measure insulin sensitivity, MRI and DEXA scan to assess muscle and body fat distribution, VO2 max test and resting metabolic rate, and a muscle biopsy to look at how the muscle is affected by insulin and testosterone (T).

Subjects will then be randomized to one of three 12-week treatment arms, 1) Group 1 (Placebo); 2) Group 2 (Depot GnRH agonist (Zoladex) + Testosterone + placebo); or 3) Group 3 (Zoladex + Testosterone + aromatase inhibitor (anastrozole)). The rationale for this study design is as follows. Under normal physiological conditions, administration of T leads to a concomitant increase in estradiol (E2) levels due to endogenous conversion by the aromatase enzyme system. Therefore, in order to understand the relative roles of T and E2 on insulin sensitivity, one group of subjects will receive T in conjunction with the aromatase inhibitor, anastrozole.

At 13 weeks, the entire baseline evaluation including OGTT, IVGTT, resting metabolic rate and VO2 max, body composition assessment by DEXA and MRI, and muscle biopsy will be repeated. Subjects will return for a follow up visit four weeks later to measure CBC, T and PSA levels, to ensure levels are within the normal range.

研究类型

介入性

注册 (预期的)

72

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Maryland
      • Baltimore、Maryland、美国、21224
        • Johns Hopkins Bayview Medical Center
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • Massachusetts General Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

50年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

男性

描述

Inclusion Criteria:

  • Age 50-75 yr
  • Diagnosis of the metabolic syndrome defined by the American Heart Association/National Heart, Lung, and Blood Institute guidelines as the presence of three or more of the following:

    • Waist circumference > 102 cm
    • Serum triglycerides > 150 mg/dL
    • HDL cholesterol < 40 mg/dL
    • Blood pressure > 130 mm Hg systolic or 85 mm Hg diastolic, or treatment with anti-hypertensives
    • Fasting serum glucose > 100 mg/dL
    • Plasma total testosterone level less than 300 ng/dL (1 SD below the mean for young healthy men)
    • Stable weight for previous three months (no weight change greater than or equal to +/-10 lbs)
    • Normal TSH, prolactin and prostate specific antigen (PSA) levels (<2.5 ng/mL)

Exclusion Criteria:

  • New diagnosis of type 2 diabetes as defined by the ADA criteria: fasting glucose greater than 126 mg/dL or random blood glucose greater than 200 mg/dL on two occasions, or on oral hypoglycemic agents
  • Contraindication to stress testing
  • Contraindication to MRI scanning (Central nervous system aneurysm clips; Implanted neural stimulator; Implanted cardiac pacemaker or defibrillator; Cochlear implant; Ocular foreign body (e.g. metal shavings); Insulin pump; Metal shrapnel or bullet)
  • History of testicular disorders (i.e. cryptorchidism)
  • History of bleeding disorders (i.e. thrombocytopenia) or baseline hemoglobin levels less than 12g/dL
  • History of metabolic bone disease (osteoporosis, osteomalacia)
  • History of prostate cancer
  • History of sleep apnea (subjects will also be excluded if at their baseline assessment they admit to heavy snoring, restless sleep, and/or excessive daytime somnolence)
  • Symptoms of urinary outflow obstruction (i.e. benign prostatic hypertrophy)
  • Illicit drug use or heavy alcohol use (>4 drinks/day)
  • Allergic disorders
  • Current medications (must exclude individuals taking the following medications):

    • Testosterone,
    • Cimetidine,
    • Spironolactone,
    • Ketoconazole,
    • Finasteride,
    • DHEA,
    • Androstenedione,
    • Oral steroids,
    • GnRH analogs

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:1
1) Group 1: Placebo
The IVGTT (70) is a 4 hour study with baseline sampling for insulin and glucose, followed by the administration of 0.3 mg/kg infusion of glucose, and subsequent frequent samples through 180 minutes. At 20 minutes, subjects will receive a 0.03 U/kg infusion of regular human insulin over 45 seconds to enhance the insulin level to better help us assess the impact of insulin on glucose uptake and to facilitate minimal model analysis. The IVGTT will be administered at baseline and after 3 months.
其他名称:
  • IVGTT
This test is employed to assess VO2max in all subjects. O2 and CO2 will be collected and measured from the expired air during the exercise stress test and used to calculate VO2max. This test will be administered at baseline and after 3 months.
1H-MR spectroscopy will be performed to measure IMCL at baseline and after 3 months.
Biopsies (20-50mg) will be obtained from the vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5 mm Bergström needle (65) with suction applied. The muscle biopsy will be performed at baseline and after 3 months.
Energy expenditure in the form of resting metabolic rate (RMR) will be measured via a metabolic monitor at baseline and after 3 months.
Total and regional percent body fat, fat mass, lean tissue mass and bone mineral content will be determined by DEXA (Lunar Prodigy version 8.50). DEXA provides an in vivo assessment of body composition with minimal requirements for subject cooperation and will be employed at baseline and after 3 months.
其他名称:
  • 得克萨
To examine glucose and insulin metabolism a standard 75g OGTT will be conducted at baseline and after 3 months.
其他名称:
  • OGTT
有源比较器:2
2) Group 2: Depot GnRH agonist (Zoladex) + Testosterone + placebo
The IVGTT (70) is a 4 hour study with baseline sampling for insulin and glucose, followed by the administration of 0.3 mg/kg infusion of glucose, and subsequent frequent samples through 180 minutes. At 20 minutes, subjects will receive a 0.03 U/kg infusion of regular human insulin over 45 seconds to enhance the insulin level to better help us assess the impact of insulin on glucose uptake and to facilitate minimal model analysis. The IVGTT will be administered at baseline and after 3 months.
其他名称:
  • IVGTT
This test is employed to assess VO2max in all subjects. O2 and CO2 will be collected and measured from the expired air during the exercise stress test and used to calculate VO2max. This test will be administered at baseline and after 3 months.
1H-MR spectroscopy will be performed to measure IMCL at baseline and after 3 months.
Biopsies (20-50mg) will be obtained from the vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5 mm Bergström needle (65) with suction applied. The muscle biopsy will be performed at baseline and after 3 months.
Energy expenditure in the form of resting metabolic rate (RMR) will be measured via a metabolic monitor at baseline and after 3 months.
Total and regional percent body fat, fat mass, lean tissue mass and bone mineral content will be determined by DEXA (Lunar Prodigy version 8.50). DEXA provides an in vivo assessment of body composition with minimal requirements for subject cooperation and will be employed at baseline and after 3 months.
其他名称:
  • 得克萨
To examine glucose and insulin metabolism a standard 75g OGTT will be conducted at baseline and after 3 months.
其他名称:
  • OGTT
transdermal 7.5 g/per day for 3 months
其他名称:
  • 雄激素 1%
single depot injection 10.8 mg 3 months
其他名称:
  • 唑雷得
有源比较器:3
3) Group 3: (Zoladex + Testosterone + aromatase inhibitor (anastrozole)
The IVGTT (70) is a 4 hour study with baseline sampling for insulin and glucose, followed by the administration of 0.3 mg/kg infusion of glucose, and subsequent frequent samples through 180 minutes. At 20 minutes, subjects will receive a 0.03 U/kg infusion of regular human insulin over 45 seconds to enhance the insulin level to better help us assess the impact of insulin on glucose uptake and to facilitate minimal model analysis. The IVGTT will be administered at baseline and after 3 months.
其他名称:
  • IVGTT
This test is employed to assess VO2max in all subjects. O2 and CO2 will be collected and measured from the expired air during the exercise stress test and used to calculate VO2max. This test will be administered at baseline and after 3 months.
1H-MR spectroscopy will be performed to measure IMCL at baseline and after 3 months.
Biopsies (20-50mg) will be obtained from the vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5 mm Bergström needle (65) with suction applied. The muscle biopsy will be performed at baseline and after 3 months.
Energy expenditure in the form of resting metabolic rate (RMR) will be measured via a metabolic monitor at baseline and after 3 months.
Total and regional percent body fat, fat mass, lean tissue mass and bone mineral content will be determined by DEXA (Lunar Prodigy version 8.50). DEXA provides an in vivo assessment of body composition with minimal requirements for subject cooperation and will be employed at baseline and after 3 months.
其他名称:
  • 得克萨
To examine glucose and insulin metabolism a standard 75g OGTT will be conducted at baseline and after 3 months.
其他名称:
  • OGTT
transdermal 7.5 g/per day for 3 months
其他名称:
  • 雄激素 1%
single depot injection 10.8 mg 3 months
其他名称:
  • 唑雷得
tablet (per oral) 10.0 mg/ daily 3 months
其他名称:
  • 瑞宁得
  • IND# 76,878

研究衡量的是什么?

主要结果指标

结果测量
大体时间
insulin sensitivity
大体时间:at baseline and after 3 months
at baseline and after 3 months

次要结果测量

结果测量
大体时间
glucose metabolism
大体时间:at baseline and after 3 months
at baseline and after 3 months
body composition VO2 max; resting metabolic rate; muscle biopsy analysis
大体时间:at baseline and after 3 months
at baseline and after 3 months
VO2 max
大体时间:at baseline and after 3 months
at baseline and after 3 months
resting metabolic rate
大体时间:at baseline and after 3 months
at baseline and after 3 months
muscle biopsy analysis
大体时间:at baseline and after 3 months
at baseline and after 3 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Frances J Hayes, MD、Massachusetts General Hospital

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2006年5月1日

初级完成 (预期的)

2011年2月1日

研究完成 (预期的)

2011年3月1日

研究注册日期

首次提交

2007年2月8日

首先提交符合 QC 标准的

2007年2月8日

首次发布 (估计)

2007年2月9日

研究记录更新

最后更新发布 (估计)

2010年3月2日

上次提交的符合 QC 标准的更新

2010年3月1日

最后验证

2010年3月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅